Subscribe

Study Summaries

CheckMate 358: Nivolumab with or without Ipilimumab in Recurrent/Metastatic Cervical Cancer

Nivolumab alone or in combination with ipilimumab shows promise in recurrent or metastatic cervical cancer, with significant objective response rates and manageable safety profiles.

GOG-LAP2: Laparoscopy Compared With Laparotomy for Comprehensive Surgical Staging of Uterine Cancer

Laparoscopic surgical staging for uterine cancer is feasible and safe, showing fewer complications and shorter hospital stays compared to laparotomy

OV-HIPEC 1: Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer

The addition of HIPEC to interval cytoreductive surgery for stage III epithelial ovarian cancer significantly improves recurrence-free and overall survival without an increase in severe side effects.

GOG 279: Cisplatin, Gemcitabine, and IMRT for Locally Advanced Vulvar Carcinoma

Weekly Cisplatin and Gemcitabine concurrent with IMRT improved CPR in women with locally advanced vulvar squamous cell carcinoma not amenable to surgical resection.

GOG 261: Carboplatin-Paclitaxel Versus Ifosfamide-Paclitaxel in Carcinosarcoma

Carboplatin/Taxol is not inferior to Ifos/Taxol in terms of OS and significantly increases PFS, making it a new standard treatment for carcinosarcoma

KEYNOTE A18: Pembrolizumab Plus Chemoradiotherapy for High-Risk Locally Advanced Cervical Cancer

Pembrolizumab combined with chemoradiotherapy and then continued post-chemoradiotherapy demonstrates significant improvements in progression-free survival and OS compared to chemoradiotherapy alone

CALLA: Durvalumab versus Placebo with Chemoradiotherapy for Locally Advanced Cervical Cancer

Durvalumab concurrent with chemoradiotherapy was well tolerated but did not significantly improve progression-free survival compared to placebo in a biomarker-unselected all-comers population for locally advanced cervical cancer

SCORPION: Primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer

Neoadjuvant chemotherapy and primary debulking surgery showed similar efficacy in terms of progression-free and overall survival. However, neoadjuvant chemotherapy resulted in significantly lower rates of post-operative complications, suggesting a different toxicity profile

GOG 249: Vaginal Brachytherapy Plus Chemotherapy vs Pelvic Radiation in High-Risk Early-Stage Endometrial Cancer

The study did not demonstrate superiority or equivalence due to similar outcomes in both arms. The higher incidence of pelvic/para-aortic nodal failures in the VCB/C arm suggests the importance of pelvic RT in preventing regional recurrences.

KEYNOTE 775: Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer

Lenvatinib plus pembrolizumab significantly improves progression-free and overall survival compared to chemotherapy among patients with advanced endometrial cancer.